TABLE 1.
Demographic data of patients enrolled in study
| Characteristics | n | N (%) |
|---|---|---|
| Number of participants, n (%) | 20 | |
| Sex, n | 20 | |
| Male | 16 (80.00) | |
| Female | 4 (20.00) | |
| Age, years, median (IQR) a | 20 | 50 (43.50–59.30) |
| Body mass index (BMI), median (IQR) a | 20 | 28 (24–32) |
| Indication for buprenorphine treatment | 20 | |
| Pain | 5 (25.00) | |
| Opioid dependence | 15 (75.00) | |
| Dose of buprenorphine, mg, median (IQR) a | 20 | 14 (4–24) |
| Duration of treatment on current dose of buprenorphine, days, median (IQR) a | 217 (77–364) | |
| Dosing site | 20 | |
| Pharmacy | 9 (45.00) | |
| Outpatient hospital clinic | 11 (55.00) | |
| Number of days out of 28 observed dosing | 20 | |
| <7 | 10 (50.00) | |
| 7–14 | 0 (0.00) | |
| 14–28 | 10 (50.00) | |
| Organ dysfunction (%) | 20 | |
| Liver impairment b | 3 (15.00) | |
| Kidney impairment c | 2 (10.00) | |
| Pre‐existing mental health diagnosis | 20 | |
| Yes | 8 (40.00) | |
| No | 12 (60.00) | |
| Co‐prescription of CYP3A4 interacting medication, number of participants | 20 | |
| Inducer | 1 (5.00) | |
| Inhibitor | 4 (20.00) | |
| Substrate | 8 (40.00) | |
| Prior history of blood‐borne virus | 20 | |
| HCV | 4 (20.00) | |
| HBV | 0 (0.00) | |
| HIV | 0 (0.00) | |
| Co‐infection with HCV, HBV, HIV | 1 (5.00) |
a
IQR; interquartile range.
b
Liver impairment defined as presence or absence of documented cirrhosis.
c
Kidney impairment defined as estimated glomerular filtration rate (eGFR) less than the lower limit of normal for age.